Skip to main content
Publications
Abtahi S, Pajouheshnia R, Duran CE, Riera-Arnau J, Gamba M, Alsina E, Hoxhaj V, Andersen M, Bartolini C, Kristiansen SB, Brown J, Hallgreen CE, Garcia-Poza P, Gardarsdottir H, Gini R, Girardi A, Holthuis E, Huerta C, Ibanez L, Limoncella G, Martin-Perez M, Paoletti O, Roberto G, Souverein P, Swart KMA, Wing K, Sturkenboom M, Klungel O. Impact of 2018 EU Risk minimisation measures and revised pregnancy prevention programme on utilisation and prescribing trends of medicinal products containing valproate: an interrupted time series study. Drug Saf. 2023 Jul;46(7):689-702. doi: 10.1007/s40264-023-01314-3
Johannes CB, Beachler DC, Layton JB, Danysh HE, Ziemiecki R, Arana A, Dinh J, Li L, Calingaert B, Pladevall-Vila M, Hunt PR, Chen H, Karlsson C, Johnsson K, Gilsenan A. Post-authorization safety study of hospitalization for acute kidney injury in patients with type 2 diabetes exposed to dapagliflozin in a real-world setting. Drug Saf. 2023 Feb 1;46(2):157-74. doi: 10.1007/s40264-022-01263-3
Danysh HE, Johannes CB, Beachler DC, Layton JB, Ziemiecki R, Arana A, Dinh J, Li L, Calingaert B, Pladevall-Vila M, Hunt PR, Chen H, Karlsson C, Johnsson K, Gilsenan A. Post-authorization safety studies of acute liver injury and severe complications of urinary tract infection in patients with type 2 diabetes exposed to dapagliflozin in a real-world setting. Drug Saf. 2023 Feb 1;46(2):175-93. doi: 10.1007/s40264-022-01262-4
Abtahi S, Pajouheshnia R, Duran-Salinas C, Riera-Arnau J, Gamba M, Alsina E, Hallgreen CE, Limoncella G, Bartolini C, Holthuis E, Martin-Perez M, Brown J, Sturkenboom M, Klungel O, Other Lot Consortium Members of the Valproate study. Impact of 2018 EU risk minimisation measures and revised pregnancy prevention programme on utilisation and prescribing trends of valproates. Poster presented at the 21st International Society of Pharmacovigilance (ISoP) Annual Meeting 2022; September 20, 2022. Verona, Italy. [abstract] Drug Saf. 2022 Aug 29; 45:1312-3. doi: 10.1007/s40264-022-01219-7
Abtahi S, Pajouheshnia R, Duran-Salinas C, Riera-Arnau J, Gamba M, Alsina E, Hallgreen CE, Limoncella G, Bartolini C, Martin-Perez M, Brown J, Sturkenboom M, Klungel O, Other Lot4 Consortium Members of the Valproate study1. Impact of the 2018 pregnancy prevention program on the use of oral retinoids in childbearing age females in Europe. Presented at the 21st International Society of Pharmacovigilance (ISoP) Annual Meeting 2022; September 20, 2022. Verona, Italy. [abstract] Drug Saf. 2022 Aug 29; 45:1111-327. doi: 10.1007/s40264-022-01219-7
Beau-Lejdstrom R, Hong LS, Garcia de Albeniz X, Floricel F, Lorenzen J, Bonfitto F, Kalilani L, Loesch C, Luscombe G, Perez-Gutthann S, Mottet I, Foskett N. Incidence of acute renal failure in patients using Levetiracetam versus other antiseizure medications: a voluntary post-authorization safety study. Drug Saf. 2022 Jul;45(7):781-90. doi: 10.1007/s40264-022-01193-0
Ersbøll AK, Sengupta K, Pukkala E, Bolin K, Aas E, Emneus M, Ramey DR, Brady JE, Mines D, Aasbjerg K, Vestergaard C, Gislason G, Born AP, Kjærulff TM. Desloratadine exposure and incidence of seizure: a nordic post-authorization safety study using a new-user cohort study design, 2001-2015. Drug Saf. 2021 Nov;44(11):1231-42. doi: 10.1007/s40264-021-01106-7
Hoffman V, Hallas J, Linder M, Margulis AV, Suehs BT, Arana A, Phiri K, Enger C, Horter L, Odsbu I, Olesen M, Perez-Gutthann S, Xu Y, Kristiansen NS, Appenteng K, de Vogel S, Seeger JD, mirabegron PMR-PASS study group. Cardiovascular risk in users of mirabegron compared with users of antimuscarinic treatments for overactive bladder: findings from a non-interventional, multinational, cohort study. Drug Saf. 2021 Aug;44(8):899-915. doi: 10.1007/s40264-021-01095-7
Switchenko JM, Roy SL, Munoz F, Lopez G, Rivera JG, Cuellar VM, Juliao P, Lopez B, Thornton A, Patel JC, Alvarez M, Reyes L, Derado G, Arvelo W, Lindblade KA. Evaluation of residential structures not covered by aerial photographs used to generate a sampling frame – Nueva Santa Rosa, Guatemala. J Glob Health. 2021 Jul 6;5:e2021056. doi: 10.29392/001c.24585
Elmasry MA, Sampani K, Abdelal OM, Fleming A, Souka A, Elbaha S, Silva PS, Sun JK, Aiello LP. Disparity of microaneurysm count between ultrawide field color imaging (UWF-CI) and ultrawide field fluorescein angiography (UWF-FA) in eyes with diabetic retinopathy. Poster presented at the ARVO Annual Meeting; May 3, 2020. Baltimore, MD. [abstract] Invest Ophth Vis Sci. 2020 Jun; 61(7):5306.
Silva PS, Cavallerano J, Elmasry MA, Fleming A, van Hemert J, Lewis D, Bhaskar V, Tolson A, Tolls D, Sun JK, Aiello LP. Impact of visible retinal area on diabetic retinopathy severity and detection of predominantly peripheral lesions when using ultrawide field imaging. Poster presented at the ARVO Annual Meeting; May 3, 2020. Baltimore, MD. [abstract] Invest Ophth Vis Sci. 2020 Jun 1; 61(7):3201.
Gilsenan A, Fortuny J, Cainzos-Achirica M, Cantero OF, Flynn RWV, Garcia-Rodriguez L, Harding A, Kollhorst B, Karlsson P, Linner L, MacDonald TM, Odsbu E, Plana E, Ruigomez A, Schink T, Ziemiecki R, Andrews EB. Cardiovascular safety of prucalopride in patients with chronic constipation: a multinational population-based cohort study. Drug Saf. 2019 Oct;42(10):1179-90. doi: 10.1007/s40264-019-00835-0
Fortuny J, Gilsenan A, Cainzos-Achirica M, Cantero OF, Flynn RWV, Garcia-Rodriguez L, Kollhorst B, Karlsson P, Linner L, MacDonald TM, Plana E, Ruigomez A, Schink T, Ziemiecki R, Andrews EB. Study design and cohort comparability in a study of major cardiovascular events in new users of prucalopride versus polyethylene glycol 3350. Drug Saf. 2019 Oct;47(10):1167-77. doi: 10.1007/s40264-019-00836-z
Shokrollahi S, Elmasry MA, Sampani K, Pisig AU, Abdelal O, Robertson G, Fleming A, Pitoc CM, Sun JK, Silva PS, Aiello LP. Association of ultrawide field (UWF) retinal vessel caliber with diabetic retinopathy (DR) severity, predominantly peripheral lesions (PPL) and retinal nonperfusion (NP). Poster presented at the 2019 ARVO Annual Meeting; April 28, 2019. Vancouver, Canada. [abstract] Invest Ophth Vis Sci. 2019 Jul 1; 60(9):4771.
Silva PS, Stanton RC, Elmasry MA, Fleming A, Pellegrini E, van Hemert J, Tolls D, Tolson AM, Lewis D, Stainback J, Cavallerano JD, Sun JK, Aiello LP. Association of systemic comorbities with predominantly peripheral diabetic retinopathy lesions (PPL) identified on ultrawide field (UWF) retinal imaging. Poster presented at the 2019 ARVO Annual Meeting; April 28, 2019. Vancouver, Canada. [abstract] Invest Ophth Vis Sci. 2019 Jul 1; 60(9):4772.
Pisig AU, Sampani K, Elmasry MA, Aldairy Y, Robertson G, Fleming A, Pitoc C, Rhee J, Sun JK, Silva PS, Aiello LP. Regional vessel caliber, retinal oximetry and predominantly peripheral diabetic retinal lesions as surrogate markers of nonperfusion on ultrawide field angiography in diabetic eyes. Poster presented at the 2018 ARVO Annual Meeting; April 29, 2018. Honolulu, HI. [abstract] Invest Ophth Vis Sci. 2018 Jul 1; 59(9):3448.
Sears CM, Hirano T, Nittala MG, Mehta NS, Sinha S, Jayadev C, Singh G, Verhoek M, Fleming A, van Hmert J, Tsui I, Prasad P, Sadda SR. Ethnic variation in diabetic retinopathy lesion distribution. Poster presented at the 2018 ARVO Annual Meeting; April 29, 2018. Honolulu, HI. [abstract] Invest Ophth Vis Sci. 2018 Jul 1; 59(9):4681.
Rasmussen K, Belisario JM, Wark PA, Molina JA, Loong SL, Cotic Z, Papachristou N, Riboli-Sasco E, Tudor Car L, Musulanov EM, Kunz H, Zhang Y, George PP, Heng BH, Wheeler EL, Al Shorbaji N, Svab I, Atun R, Majeed A, Car J. Offline eLearning for undergraduates in health professions: a systematic review of the impact on knowledge, skills, attitudes and satisfaction. J Glob Health. 2014 Jun;4(1):010405. doi: 10.7189/jogh.04.010405
George PP, Papachristou N, Marcano Belisario J, Wang W, Wark PA, Cotic Z, Rasmussen K, Sluiter R, Riboli-Sasco E, Tudor Car L, Musulanov EM, Molina JA, Heng BH, Zhang Y, Wheeler EL, Shorbaji NA, Majeed A, Car J. Online eLearning for undergraduates in health professions: a systematic review of the impact on knowledge, skills, attitudes and satisfaction. J Glob Health. 2014 Jun;4(1):010406. doi: 10.7189/jogh.04.010406
Gulmez SE, Larrey D, Pageaux GP, Lignot S, Lassalle R, Jove J, Gatta A, McCormick A, Metselaar HJ, Monteiro E, Thorburn D, Bernal W, Zouboulis-Vafiadis I, de Vries C, Perez-Gutthann S, Sturkenboom M, Benichou J, Montastruc JL, Horsmans Y, Salvo F, Hamoud F, Micon S, Droz-Perroteau C, Blin P, Moore N. Transplantation for acute liver failure in patients exposed to NSAIDs or Paracetamol (acetaminophen): the multinational case-population SALT study. Drug Saf. 2013 Feb 1;36(2):135-44.
Arana A, Allen S, Burkowitz J, Fantoni V, Ghatnekar O, Rico MT, Vanhaverbeke N, Wentworth CE, Brosa M, Arellano FM. Infliximab paediatric Crohn's disease educational plan: a European, cross-sectional, multicentre evaluation. Drug Saf. 2010 Jun;33(6):489-501.